No Data
Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...
Catalent Gains After Report Sale to Novo Holdings Could Close Soon
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
